| Year |
Citation |
Score |
| 2024 |
Abla O, Ries RE, Triche TJ, Gerbing RB, Hirsch B, Raimondi S, Cooper TM, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, ... Alonzo T, et al. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Advances. PMID 38306602 DOI: 10.1182/bloodadvances.2023010805 |
0.361 |
|
| 2023 |
Cooper TM, Alonzo TA, Tasian SK, Kutny MA, Hitzler J, Pollard JA, Aplenc R, Meshinchi S, Kolb EA. Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. Pediatric Blood & Cancer. e30584. PMID 37480164 DOI: 10.1002/pbc.30584 |
0.337 |
|
| 2022 |
Pommert L, Cooper TM, Gerbing RB, Brodersen L, Loken M, Gamis A, Aplenc R, Alonzo TA, Kolb EA. Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers. 14. PMID 35158884 DOI: 10.3390/cancers14030616 |
0.319 |
|
| 2021 |
Huang BJ, Smith J, Wang J, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing RB, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, ... ... Alonzo T, et al. CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes. Blood Advances. PMID 34547772 DOI: 10.1182/bloodadvances.2021004965 |
0.339 |
|
| 2021 |
Hitzler JK, Alonzo T, Gerbing RB, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola SA, Eidenschink Brodersen L, Loken MR, Tong RS, Druley TE, O'Brien MM, Hijiya N, Heerema-McKenney AE, et al. High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531. Blood. PMID 34320162 DOI: 10.1182/blood.2021012206 |
0.351 |
|
| 2020 |
Brodersen LE, Gerbing RB, Pardo ML, Alonzo TA, Paine D, Fritschle W, Hsu FC, Pollard JA, Aplenc R, Kahwash SB, Hirsch B, Ramondi S, Wells D, Kolb EA, Gamis AS, et al. Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances. 4: 5050-5061. PMID 33080007 DOI: 10.1182/bloodadvances.2020002070 |
0.369 |
|
| 2020 |
Hoff FW, van Dijk AD, Qiu YH, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo T, Meshinchi S, De Bont E, Bruggeman SW, Kornblau SM, et al. Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study. Blood. PMID 32959058 DOI: 10.1182/Blood.2020005208 |
0.397 |
|
| 2020 |
Dang HM, Alonzo T, Franklin M, Mack WJ, Krailo MD, Eckel SP. Information fraction estimation based on the number of events within the standard treatment regimen. Biometrical Journal. Biometrische Zeitschrift. PMID 32627859 DOI: 10.1002/Bimj.201900236 |
0.301 |
|
| 2020 |
Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903306. PMID 32401633 DOI: 10.1200/Jco.19.03306 |
0.36 |
|
| 2020 |
Noort S, Wander P, Alonzo TA, Smith J, Ries RE, Gerbing RB, Dolman MEM, Locatelli F, Reinhardt D, Baruchel A, Stary J, Molenaar JJ, Stam RW, van den Heuvel-Eibrink MM, Zwaan CM, et al. The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. Haematologica. PMID 32381579 DOI: 10.3324/Haematol.2019.236745 |
0.338 |
|
| 2020 |
Getz KD, Sung L, Alonzo TA, Leger KJ, Gerbing RB, Pollard JA, Cooper T, Kolb EA, Gamis AS, Ky B, Aplenc R. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902856. PMID 32343641 DOI: 10.1200/Jco.19.02856 |
0.416 |
|
| 2020 |
Tarlock K, Alonzo T, Wang YC, Gerbing RB, Ries RE, Hylkema T, Smith J, Maxson JE, Meshinchi S. Prognostic Impact of CSF3R Mutations in Favorable Risk Childhood Acute Myeloid Leukemia. Blood. PMID 32187354 DOI: 10.1182/Blood.2019004179 |
0.344 |
|
| 2020 |
Phillips CL, Lane A, Gerbing RB, Alonzo TA, Radloff GA, Wilkey A, Lange B, Gamazon ER, Dolan ME, Davies SM. Genomic variants of cytarabine sensitivity associated with treatment related mortality in pediatric AML: A report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32122921 DOI: 10.1158/1078-0432.Ccr-19-3117 |
0.343 |
|
| 2020 |
Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Khawash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. PMID 32029509 DOI: 10.3324/Haematol.2019.220962 |
0.467 |
|
| 2020 |
Leger KJ, Absalon M, Demissei BG, Gerbing RB, Alonzo TA, Hirsch BA, Pollard JA, Razzouk BI, Kolb EA, Aplenc R, Ky B, Cooper TM. Change in cardiac function with CPX-351 in relapsed pediatric AML: A Children’s Oncology Group (COG) report from AAML1421. Journal of Clinical Oncology. 38: 10532-10532. DOI: 10.1200/Jco.2020.38.15_Suppl.10532 |
0.38 |
|
| 2019 |
Davies SM, Iannone R, Alonzo TA, Wang YC, Gerbing R, Soni S, Kolb EA, Meshinchi S, Orchard PJ, Burns LJ, Shenoy S, Leung W. A Phase 2 Trial of KIR Mismatched Unrelated Donor Transplantation Using In Vivo T-cell Depletion with ATG in AML: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31870931 DOI: 10.1016/J.Bbmt.2019.12.723 |
0.394 |
|
| 2019 |
Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, et al. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31719049 DOI: 10.1158/1078-0432.Ccr-19-1800 |
0.341 |
|
| 2019 |
Orgel E, Alexander TB, Wood BL, Kahwash SB, Devidas M, Dai Y, Alonzo TA, Mullighan CG, Inaba H, Hunger SP, Raetz EA, Gamis AS, Rabin KR, Carroll AJ, Heerema NA, et al. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. PMID 31661160 DOI: 10.1002/Cncr.32552 |
0.356 |
|
| 2019 |
Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Raimondi SC, Hirsch B, Hitzler JK, Head DR. Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. Archives of Pathology & Laboratory Medicine. PMID 31429606 DOI: 10.5858/Arpa.2018-0526-Oa |
0.344 |
|
| 2019 |
Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Brodersen LE, Loken MR. Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Cytometry. Part B, Clinical Cytometry. PMID 31294507 DOI: 10.1002/Cyto.B.21829 |
0.389 |
|
| 2019 |
Nagarajan R, Gerbing R, Alonzo T, Johnston DL, Aplenc R, Kolb EA, Meshinchi S, Barakat LP, Sung L. Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group. Cancer Medicine. PMID 31190442 DOI: 10.1002/Cam4.2337 |
0.335 |
|
| 2019 |
Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries RE, Hylkema T, Joaquin J, Sarukkai L, Raimondi S, Hirsch BA, Sung L, Aplenc R, Bernstein ID, Gamis AS, Meshinchi S, et al. Functional Properties of KIT Mutations are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31182436 DOI: 10.1158/1078-0432.Ccr-18-1897 |
0.344 |
|
| 2019 |
Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer Journal. 9: 51. PMID 31113932 DOI: 10.1038/S41408-019-0211-Y |
0.366 |
|
| 2019 |
Murphy BR, Roth M, Kolb EA, Alonzo T, Gerbing R, Wells RJ. Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. Pediatric Blood & Cancer. e27700. PMID 30908863 DOI: 10.1002/Pbc.27700 |
0.415 |
|
| 2019 |
McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, Shah M, Arora K, Emde AK, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. PMID 30760869 DOI: 10.1038/S41375-019-0402-3 |
0.38 |
|
| 2019 |
Parsons DW, Janeway KA, Patton D, Coffey B, Williams PM, Hamilton SR, Purkayastha A, Tsongalis GJ, Routbort M, Gastier-Foster JM, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, et al. Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. Journal of Clinical Oncology. 37: 10011-10011. DOI: 10.1200/Jco.2019.37.15_Suppl.10011 |
0.32 |
|
| 2019 |
Cooper TM, Absalon M, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard JA, Razzouk BI, Aplenc R, Kolb EA. AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group. Journal of Clinical Oncology. 37: 10003-10003. DOI: 10.1200/Jco.2019.37.15_Suppl.10003 |
0.368 |
|
| 2019 |
Aplenc R, Sung L, Pollard JA, Brodersen L, Loken M, Gerbing RB, Getz KD, Meshinchi S, Woods WG, Kolb EA, Alonzo TA, Gamis AS. Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 37: 10002-10002. DOI: 10.1200/Jco.2019.37.15_Suppl.10002 |
0.427 |
|
| 2019 |
Getz KD, Sung L, Gerbing RB, Alonzo TA, Li Y, Huang YV, Leger KJ, Pollard JA, Cooper TM, Kolb EA, Gamis AS, Aplenc R. Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group Blood. 134: 331-331. DOI: 10.1182/Blood-2019-131227 |
0.442 |
|
| 2019 |
Winestone LE, Getz KD, Bona KO, Fisher BT, Gamis AS, Seif AE, Sung L, Wang Y, Alonzo TA, Aplenc R. Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 134: 703-703. DOI: 10.1182/Blood-2019-130978 |
0.393 |
|
| 2019 |
Pollard JA, Alonzo TA, Brown PA, Gerbing RB, Fox E, Choi JK, Fisher BT, Hirsch BA, Kahwash S, Levine JE, Loken MR, Raimondi SC, Tarlock K, Wood AC, Sung L, et al. Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031 Blood. 134: 292-292. DOI: 10.1182/Blood-2019-129557 |
0.419 |
|
| 2019 |
van Dijk AD, Ruvolo PP, Hoff FW, Qiu Y, Gamis AS, Aplenc R, Kolb AE, Alonzo TA, Gerbing RB, de Bont ES, Bruggeman SW, Horton TM, Kornblau SM. Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial Blood. 134: 2676-2676. DOI: 10.1182/Blood-2019-128579 |
0.438 |
|
| 2019 |
Tarlock K, Pollard JA, Alonzo TA, Gerbing RB, Wang Y, Ries RE, Smith JL, Kolb EA, Gamis AS, Aplenc R, Meshinchi S. Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile Blood. 134: 119-119. DOI: 10.1182/Blood-2019-127569 |
0.418 |
|
| 2019 |
Smith JL, Ries RE, Farrar JE, Alonzo TA, Gerbing RB, Leonti AR, Hylkema TA, Gamis AS, Aplenc R, Kolb EA, Nguyen C, Meerzaman D, Triche TJ, Meshinchi S. Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia - a COG and Tpaml Study Blood. 134: 2741-2741. DOI: 10.1182/Blood-2019-127318 |
0.433 |
|
| 2019 |
Tarlock K, Eidenschink Brodersen L, Alonzo TA, Wang Y, Gerbing RB, Pardo L, Dai F, Gamis AS, Aplenc R, Pollard JA, Loken MR, Meshinchi S. CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia Blood. 134: 2699-2699. DOI: 10.1182/Blood-2019-127100 |
0.369 |
|
| 2019 |
Hitzler JK, Berman J, Gerbing RB, Beckman A, Hirsch BA, Raimondi SC, Druley TE, Loken MR, Eidenschink Brodersen L, Chisholm K, Viola SA, Taub JW, Gamis AS, Alonzo TA, Kolb EA. High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction Blood. 134: 118-118. DOI: 10.1182/Blood-2019-126723 |
0.43 |
|
| 2019 |
Tarlock K, Alonzo TA, Wang Y, Gerbing RB, Ries RE, Hylkema TA, Woods WG, Cooper TM, Gamis AS, Aplenc R, Meshinchi S. Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation Blood. 134: 181-181. DOI: 10.1182/Blood-2019-126273 |
0.375 |
|
| 2019 |
Ries RE, Leonti AR, Triche TJ, Gerbing RB, Hirsch BA, Raimondi SC, Smith JL, Cooper TM, Farrar JE, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study Blood. 134: 461-461. DOI: 10.1182/Blood-2019-125943 |
0.421 |
|
| 2019 |
Lamble AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, Gerbing RB, Pardo L, Sung L, Tasian SK, Cooper TM, Kolb EA, Aplenc R, Loken MR, Meshinchi S. Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 134: 459-459. DOI: 10.1182/Blood-2019-124587 |
0.397 |
|
| 2019 |
Leonti AR, Pardo L, Alonzo TA, Gerbing RB, Eidenschink Brodersen L, Ries RE, Smith JL, Le Q, Aplenc R, Kolb EA, Magnani JL, Fogler WE, Loken MR, Meshinchi S. Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML Blood. 134: 3772-3772. DOI: 10.1182/Blood-2019-124525 |
0.366 |
|
| 2019 |
McNeer N, Philip J, Geiger H, Ries RE, Lavallee V, Walsh M, Shah M, Arora K, Emde A, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, et al. Abstract 2870: Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2870 |
0.305 |
|
| 2018 |
Withycombe JS, Alonzo TA, Wilkins-Sanchez MA, Hetherington M, Adamson PC, Landier W. The Children's Oncology Group: Organizational Structure, Membership, and Institutional Characteristics. Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses. 1043454218810141. PMID 30426816 DOI: 10.1177/1043454218810141 |
0.306 |
|
| 2018 |
Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Leahy AB, Sack L, Woods WG, Alonzo T, Gamis A, Aplenc R. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800313. PMID 30379624 DOI: 10.1200/Jco.18.00313 |
0.407 |
|
| 2018 |
Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M, Smith J, Ries RE, Alonzo TA, Hirsch B, Tomizawa D, Locatelli F, Gruber TA, Raimondi S, Sonneveld E, Cheuk DK, et al. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood. PMID 30150206 DOI: 10.1182/Blood-2018-05-849059 |
0.396 |
|
| 2018 |
Rajpurkar M, Alonzo TA, Wang YC, Gerbing RB, Gamis AS, Feusner JH, Gregory J, Kutny MA. Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. Journal of Pediatric Hematology/Oncology. PMID 30095694 DOI: 10.1097/Mph.0000000000001280 |
0.381 |
|
| 2018 |
Getz KD, Sung L, Leger K, Alonzo TA, Gerbing RB, Cooper TM, Kolb E, Gamis AS, Ky B, Aplenc R. Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Children’s Oncology Group report. Journal of Clinical Oncology. 36: 10501-10501. DOI: 10.1200/Jco.2018.36.15_Suppl.10501 |
0.406 |
|
| 2018 |
Chae H, Murphy LC, Donato M, Lee AG, Sweet-Cordero EA, Abidi P, Bittencourt H, Lacayo NJ, Dahl GVH, Aftandilian C, Davis KL, Huang M, Sumarsono N, Redell M, Fu CH, ... ... Alonzo TA, et al. Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells Blood. 132: 4246-4246. DOI: 10.1182/Blood-2018-99-119974 |
0.355 |
|
| 2018 |
Narayanan P, Wang Y, Man CT, Ries RE, Gerbing RB, Meshinchi S, Alonzo TA, Redell M. Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML Blood. 132: 1510-1510. DOI: 10.1182/Blood-2018-99-118771 |
0.322 |
|
| 2018 |
Pardo L, Eidenschink Brodersen L, Lamba JK, Alonzo TA, Wang Y, Paine D, Gamis AS, Kolb EA, Pollard JA, Cooper TM, Aplenc R, Meshinchi S, Loken MR. Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 Blood. 132: 1490-1490. DOI: 10.1182/Blood-2018-99-115053 |
0.316 |
|
| 2018 |
Tarlock K, Alonzo TA, Gerbing RB, Ries RE, Gibson B, Niktoreh N, Noort S, Van den Heuvel-Eibrink MM, Zwaan CM, Meshinchi S. Distinct Co-Occurring Mutational Profiles in Acute Myeloid Leukemia Confers Prognostic Significance in Children and Young Adults with FLT3/ITD Mutations Blood. 132: 443-443. DOI: 10.1182/Blood-2018-99-113676 |
0.425 |
|
| 2018 |
Nagarajan R, Alonzo TA, Gerbing RB, Johnston D, Aplenc R, Kolb EA, Meshinchi S, Barakat L, Sung L. Quality of Life in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 132: 4841-4841. DOI: 10.1182/Blood-2018-99-112152 |
0.415 |
|
| 2018 |
Hoff FW, Qiu Y, Hu W, Qutub AA, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, de Bont ES, Horton TM, Kornblau SM. Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia Blood. 132: 294-294. DOI: 10.1182/Blood-2018-99-110796 |
0.367 |
|
| 2018 |
Hoff FW, Hu W, Qiu Y, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Qutub AA, de Bont ES, Bruggeman SW, Kornblau SM, Horton TM. RPPA-Profiling Identifies Patients with Low Phosphorylation Levels of HSF1 at Serine 326 As Potential Candidate for Bortezomib Treatment in Addition to Standard Therapy in Pediatric Acute Myeloid Leukemia Blood. 132: 293-293. DOI: 10.1182/Blood-2018-99-110730 |
0.382 |
|
| 2018 |
Narayanan P, Dubrulle J, Gerbing RB, Alonzo TA, Stossi F, Redell MS. Abstract 3550: Lipid rafts contribute to ligand-induced signaling and survival in pediatric AML Cancer Research. 78: 3550-3550. DOI: 10.1158/1538-7445.Am2018-3550 |
0.314 |
|
| 2017 |
Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine. PMID 29227476 DOI: 10.1038/Nm.4439 |
0.356 |
|
| 2017 |
Long X, Gerbing RB, Alonzo TA, Redell MS. Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Children's Oncology Group report. Oncotarget. 8: 90037-90049. PMID 29163809 DOI: 10.18632/Oncotarget.21363 |
0.323 |
|
| 2017 |
Lim EL, Trinh DL, Ries RE, Wang J, Gerbing RB, Ma Y, Topham J, Hughes M, Pleasance E, Mungall AJ, Moore R, Zhao Y, Aplenc R, Sung L, Kolb EA, ... ... Alonzo TA, et al. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017747451. PMID 29068783 DOI: 10.1200/Jco.2017.74.7451 |
0.319 |
|
| 2017 |
Voigt AP, Eidenschink Brodersen L, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Loken MR. Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. Haematologica. PMID 28883080 DOI: 10.3324/Haematol.2017.169029 |
0.41 |
|
| 2017 |
Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH, Gregory JJ. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016716183. PMID 28767288 DOI: 10.1200/Jco.2016.71.6183 |
0.443 |
|
| 2017 |
Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531. Blood. PMID 28674028 DOI: 10.1182/Blood-2017-01-762336 |
0.342 |
|
| 2017 |
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016712513. PMID 28644774 DOI: 10.1200/Jco.2016.71.2513 |
0.382 |
|
| 2017 |
Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, et al. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Haematologica. PMID 28642300 DOI: 10.3324/Haematol.2017.168815 |
0.398 |
|
| 2017 |
Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS. Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 28453910 DOI: 10.1002/Pbc.26612 |
0.401 |
|
| 2017 |
Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K. Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. Journal of Clinical Pharmacology. PMID 28419486 DOI: 10.1002/Jcph.906 |
0.365 |
|
| 2017 |
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. PMID 28411282 DOI: 10.1182/Blood-2017-03-772384 |
0.434 |
|
| 2017 |
Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. PMID 28389462 DOI: 10.1182/Blood-2017-01-764324 |
0.447 |
|
| 2017 |
Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi S, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S. Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28108543 DOI: 10.1158/1078-0432.Ccr-16-2353 |
0.36 |
|
| 2017 |
Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch BA, Kahwash SB, Choi J, Kolb EA, Gamis AS, Aplenc R. Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children’s Oncology Group report. Journal of Clinical Oncology. 35: 10515-10515. DOI: 10.1200/Jco.2017.35.15_Suppl.10515 |
0.439 |
|
| 2017 |
Orgel E, Alexander TB, Wood B, Kahwash S, Devidas M, Dai Y, Alonzo TA, Mullighan CG, Inaba H, Hunger SP, Gamis AS, Carroll AJ, Heerema NA, Berman J, Woods WG, et al. Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group Blood. 130: 883-883. DOI: 10.1182/Blood.V130.Suppl_1.883.883 |
0.4 |
|
| 2017 |
Cooper TM, Ries RE, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Raimondi SC, Hirsch BA, Aplenc R, Gamis AS, Kolb EA, Meshinchi S. Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 130: 407-407. DOI: 10.1182/Blood.V130.Suppl_1.407.407 |
0.459 |
|
| 2017 |
Brodersen LE, Alonzo TA, Gerbing RB, Kolb A, Gamis AS, Aplenc R, Meshinchi S, Loken MR. Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031 Blood. 130: 3905-3905. DOI: 10.1182/Blood.V130.Suppl_1.3905.3905 |
0.341 |
|
| 2017 |
Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Barz A, Sack L, Woods WG, Alonzo TA, Gamis AS, Aplenc R. Occurrence of Cardiotoxicity and the Impact on Outcomes Among Children Treated on the AAML0531 Clinical Trial: A Report from the Children's Oncology Group Blood. 130: 3875-3875. DOI: 10.1182/Blood.V130.Suppl_1.3875.3875 |
0.418 |
|
| 2017 |
Davies SM, Iannone R, Alonzo T, Wang J, Gerbing R, Soni S, Kolb EA, Meshinchi S, Orchard P, Burns LJ, Shenoy S, Leung WH. A Prospective Phase 2 Clinical Trial of KIR Mismatched Unrelated Donor Transplantation for Children and Young Adults with High Risk AML: A Report of Children's Oncology Group AAML05P1 Study Biology of Blood and Marrow Transplantation. 23: S134-S135. DOI: 10.1016/J.Bbmt.2017.01.053 |
0.36 |
|
| 2016 |
Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM, Alonzo TA, Meshinchi S, Stone RM, Kornblau SM, Marcucci G, et al. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology. PMID 27766616 DOI: 10.1111/Bjh.14413 |
0.352 |
|
| 2016 |
Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. Journal of Hematology & Oncology. 9: 82. PMID 27599459 DOI: 10.1186/S13045-016-0312-Z |
0.375 |
|
| 2016 |
Vujkovic M, Aplenc R, Alonzo TA, Gamis AS, Li Y. Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. Frontiers in Genetics. 7: 139. PMID 27547214 DOI: 10.3389/Fgene.2016.00139 |
0.343 |
|
| 2016 |
Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. Pediatric Blood & Cancer. PMID 27511899 DOI: 10.1002/Pbc.26157 |
0.314 |
|
| 2016 |
Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Alonzo T, Gerbing R, Sung L, Hall M, Bagatell R, Gamis A, Fisher BT, Aplenc R. Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. Cancer Medicine. PMID 27474232 DOI: 10.1002/Cam4.839 |
0.385 |
|
| 2016 |
Gerbing RB, Alonzo TA, Sung L, Gamis AS, Meshinchi S, Plon SE, Bertuch AA, Gramatges MM. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27354474 DOI: 10.1200/Jco.2016.66.9622 |
0.377 |
|
| 2016 |
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang YC, Meshinchi S, Gamis AS. Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children's Oncology Group. International Journal of Cancer. PMID 27312107 DOI: 10.1002/Ijc.30236 |
0.406 |
|
| 2016 |
Maxson JE, Ries RE, Wang YC, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, ... ... Alonzo TA, et al. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood. PMID 27143256 DOI: 10.1182/Blood-2016-04-709899 |
0.329 |
|
| 2016 |
Brodersen LE, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Loken MR. A recurrent immunophenotype at diagnosis independently identifies high risk pediatric acute myeloid leukemia: A report from children's oncology group. Leukemia. PMID 27133823 DOI: 10.1038/Leu.2016.119 |
0.392 |
|
| 2016 |
de Rooij JD, Masetti R, van den Heuvel-Eibrink MM, Cayuela JM, Trka J, Reinhardt D, Rasche M, Sonneveld E, Alonzo TA, Fornerod M, Zimmermann M, Pigazzi M, Pieters R, Meshinchi S, Zwaan CM, et al. Recurrent genetic abnormalities can be used for risk-group stratification in pediatric AMKL: results of a retrospective intergroup study. Blood. PMID 27114462 DOI: 10.1182/Blood-2016-01-695551 |
0.394 |
|
| 2016 |
Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, Alonzo TA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida L, Muzny DM, Dewal N, Rustagi N, Lewis LR, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Research. PMID 26941285 DOI: 10.1158/0008-5472.Can-15-1015 |
0.395 |
|
| 2016 |
Miller TP, Li Y, Kavcic M, Troxel AB, Huang YV, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, et al. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26884558 DOI: 10.1200/Jco.2015.65.5860 |
0.337 |
|
| 2016 |
Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786921 DOI: 10.1200/Jco.2015.62.6846 |
0.336 |
|
| 2016 |
Miller TP, Getz KD, Kavcic M, Li Y, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, et al. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leukemia & Lymphoma. 1-8. PMID 26727639 DOI: 10.3109/10428194.2015.1088652 |
0.385 |
|
| 2016 |
Aplenc R, Meshinchi S, Sung L, Alonzo TA, Pollard J, Gerbing R, Raimondi SC, Hirsch BA, Loken MR, Winter L, Kahwash SB, Choi JK, Levine JE, Kolb EA, Gamis AS. The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group Blood. 128: 899-899. DOI: 10.1182/Blood.V128.22.899.899 |
0.462 |
|
| 2016 |
Farrar JE, Bolouri H, Ries RE, Triche TJ, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Auvil JG, Davidsen TM, Gesuwan P, Hermida LC, Kolb EA, et al. Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative Blood. 128: 595-595. DOI: 10.1182/Blood.V128.22.595.595 |
0.384 |
|
| 2016 |
Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS. The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group Blood. 128: 4016-4016. DOI: 10.1182/Blood.V128.22.4016.4016 |
0.379 |
|
| 2016 |
Kutny MA, Alonzo TA, Gerbing R, Wang Y, Fu C, Gamis AS, Kolb EA, Feusner JH, Gregory J, Meshinchi S. FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial Blood. 128: 2884-2884. DOI: 10.1182/Blood.V128.22.2884.2884 |
0.448 |
|
| 2016 |
Tarlock K, Kaeding AJ, Alonzo TA, Loken MR, Ries RE, Pardo L, Gerbing R, Farrar JE, Guidry Auvil JM, Gerhard DS, Smith MA, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, et al. Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative Blood. 128: 2873-2873. DOI: 10.1182/Blood.V128.22.2873.2873 |
0.349 |
|
| 2016 |
Selim D, Alonzo TA, Othus M, Gerbing R, Ostronoff F, Tarlock K, Kutny MA, Aplenc R, Kolb EA, Radich JP, Appelbaum FR, Gamis AS, Stirewalt DL, Meshinchi S. Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration Blood. 128: 285-285. DOI: 10.1182/Blood.V128.22.285.285 |
0.42 |
|
| 2016 |
Tarlock K, Cooper TM, Alonzo TA, Gerbing R, Pollard J, Aplenc R, Kolb EA, Gamis AS, Meshinchi S. Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 128: 2846-2846. DOI: 10.1182/Blood.V128.22.2846.2846 |
0.353 |
|
| 2016 |
Cooper TM, Gerbing RB, Alonzo TA, Pollard J, Sung L, Kolb EA, Aplenc R, Meshinchi S, Gamis AS. Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group Blood. 128: 2794-2794. DOI: 10.1182/Blood.V128.22.2794.2794 |
0.446 |
|
| 2016 |
Sung L, Gerbing R, Alonzo TA, Wang Y, Orgel E, Gamis AS, Aplenc R. Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group Blood. 128: 2790-2790. DOI: 10.1182/Blood.V128.22.2790.2790 |
0.409 |
|
| 2016 |
Lamba JK, Chauhan L, Loken MR, Pollard J, Wang Y, Rhonda RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study Blood. 128: 2743-2743. DOI: 10.1182/Blood.V128.22.2743.2743 |
0.329 |
|
| 2016 |
Wilson ER, Brodersen LE, Zehentner BK, Menssen AJ, Voigt AP, Pardo L, Wells DA, Hitzler J, Berman JN, Alonzo TA, Kahwash SB, Meshinchi S, Loken MR. Down Syndrome AML Is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration Blood. 128: 1687-1687. DOI: 10.1182/Blood.V128.22.1687.1687 |
0.427 |
|
| 2016 |
Guest EM, Hirsch BA, Kolb EA, Alonzo TA, Gerbing R, Aplenc R, Pollard J, Sung L, Meshinchi S, Gamis AS, Raimondi SC. Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531 Blood. 128: 1211-1211. DOI: 10.1182/Blood.V128.22.1211.1211 |
0.385 |
|
| 2016 |
Lim EL, Trinh DL, Ries RE, Wang J, Ma Y, Topham J, Hughes MD, Pleasance E, Mungall AJ, Moore R, Zhao Y, Kolb EA, Gamis AS, Gerhard DS, Alonzo TA, et al. A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia Blood. 128: 1210-1210. DOI: 10.1182/Blood.V128.22.1210.1210 |
0.398 |
|
| 2016 |
Triche TJ, Farrar JE, Bolouri H, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida LC, Kolb EA, et al. Divergent Epigenomes in Pediatric and Adult Acute Myeloid Leukemia Implicate Cell of Origin and Transcriptional Silencing of Immune Responses As Sources of Clinically Relevant Heterogeneity: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative Blood. 128: 1046-1046. DOI: 10.1182/Blood.V128.22.1046.1046 |
0.372 |
|
| 2015 |
Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, ... ... Alonzo TA, et al. Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics. 48: 101. PMID 26711114 DOI: 10.1038/Ng0116-101A |
0.331 |
|
| 2015 |
Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A, Meshinchi S. Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26644412 DOI: 10.1182/Blood.V124.21.486.486 |
0.407 |
|
| 2015 |
Li Y, Hall M, Fisher BT, Seif AE, Huang YS, Bagatell R, Getz KD, Alonzo TA, Gerbing RB, Sung L, Adamson PC, Gamis A, Aplenc R. Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. Plos One. 10: e0143480. PMID 26606521 DOI: 10.1371/Journal.Pone.0143480 |
0.365 |
|
| 2015 |
Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26573082 DOI: 10.1200/Jco.2015.61.1947 |
0.41 |
|
| 2015 |
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of Hematology & Oncology. 8: 115. PMID 26487643 DOI: 10.1182/Blood.V126.23.2570.2570 |
0.451 |
|
| 2015 |
Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, ... ... Alonzo TA, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics. PMID 26457647 DOI: 10.1038/Ng.3400 |
0.374 |
|
| 2015 |
Stevens AM, Ruiz MJ, Gerbing RB, Alonzo TA, Gamis AS, Redell MS. Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric Acute Myeloid Leukemia: A Report from the Children' s Oncology Group. Haematologica. PMID 26294728 DOI: 10.3324/Haematol.2015.131508 |
0.357 |
|
| 2015 |
Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. Cancer Genetics. 208: 408-13. PMID 26163103 DOI: 10.1016/J.Cancergen.2015.04.010 |
0.326 |
|
| 2015 |
Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, Heerema NA, Sung L, Aplenc R, Franklin J, Raimondi SC, Hirsch BA, Konkashbaev A, Cox NJ, Onel K, et al. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. Leukemia. PMID 26126966 DOI: 10.1038/Leu.2015.171 |
0.316 |
|
| 2015 |
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, et al. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 25946708 DOI: 10.1002/Pbc.25569 |
0.347 |
|
| 2015 |
Johnston D, Gerbing R, Alonzo T, Aplenc R, Nagarajan R, Schulte F, Cullen P, Sung L. Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group. Plos One. 10: e0125290. PMID 25915772 DOI: 10.1371/Journal.Pone.0125290 |
0.375 |
|
| 2015 |
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3187-95. PMID 25825478 DOI: 10.1158/1078-0432.Ccr-14-2684 |
0.405 |
|
| 2015 |
Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, et al. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 62: 1184-9. PMID 25760019 DOI: 10.1002/Pbc.25475 |
0.374 |
|
| 2015 |
Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 62: 629-36. PMID 25704135 DOI: 10.1002/Pbc.25342 |
0.388 |
|
| 2015 |
Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, ... Alonzo TA, et al. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 125: 516-24. PMID 25395418 DOI: 10.1182/Blood-2014-09-601690 |
0.383 |
|
| 2015 |
Miller TP, Li Y, Kavcic M, Alonzo TA, Hall M, Huang Y, Gerbing RB, Fisher B, Luger SM, Rubin D, Troxel AB, Sung L, Gamis AS, Aplenc R. Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 33: 10028-10028. DOI: 10.1200/Jco.2015.33.15_Suppl.10028 |
0.374 |
|
| 2015 |
Tolbert JA, Sung L, Aplenc R, Alonzo TA, Wang YJ, Gerbing RB, Meshinchi S, Gamis AS. Gemtuzumab ozogamycin (GO) and toxic mortality (TM) in children and adolescents with acute myeloid leukemia (AML) enrolled on Children’s Oncology Group (COG) trial AAML0531. Journal of Clinical Oncology. 33: 10008-10008. DOI: 10.1200/Jco.2015.33.15_Suppl.10008 |
0.408 |
|
| 2015 |
Brown F, Still E, Cifani P, Ficarro S, Pouliot G, Drill E, Gonen M, He J, Balasubramanian S, Zhong S, Pavlick D, Yilmazel B, Krivtsov AV, Alonzo TA, Meshinchi S, et al. Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia Blood. 126: 88-88. DOI: 10.1182/Blood.V126.23.88.88 |
0.378 |
|
| 2015 |
Tarlock K, Hansen ME, Hylkema T, Ries R, Farrar JE, Auvil JG, Gerhard DS, Smith MA, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Mungall K, Ma Y, ... ... Alonzo TA, et al. Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative Blood. 126: 87-87. DOI: 10.1182/Blood.V126.23.87.87 |
0.324 |
|
| 2015 |
Pollard J, Alonzo TA, Gerbing RB, Wang Y, Joaquin J, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Bernstein ID, Gamis AS, Meshinchi S. Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 Blood. 126: 800-800. DOI: 10.1182/Blood.V126.23.800.800 |
0.42 |
|
| 2015 |
Pollard J, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Guest EM, Bernstein ID, Loken MR, Meshinchi S, Gamis AS. Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 Blood. 126: 799-799. DOI: 10.1182/Blood.V126.23.799.799 |
0.466 |
|
| 2015 |
Lim EL, Trinh DL, Ries RE, Ma Y, Topham J, Hughes MD, Pleasance E, Mungall AJ, Moore R, Zhao Y, Gerhard DS, Oehler V, Kolb EA, Gamis AS, Smith MA, ... Alonzo TA, et al. Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative Blood. 126: 687-687. DOI: 10.1182/Blood.V126.23.687.687 |
0.32 |
|
| 2015 |
Loken MR, Voigt AP, Gerbing RB, Brodersen LE, Menssen AJ, Pardo L, Gamis AS, Alonzo TA, Meshinchi S. Heirarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531 Blood. 126: 561-561. DOI: 10.1182/Blood.V126.23.561.561 |
0.375 |
|
| 2015 |
Brodersen LE, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch BA, Raimondi SC, Gamis AS, Meshinchi S, Loken MR. A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531 Blood. 126: 560-560. DOI: 10.1182/Blood.V126.23.560.560 |
0.407 |
|
| 2015 |
de Rooij J, Masetti R, van den Heuvel-Eibrink MM, Cayuela J, Trka J, Reinhardt D, Sonneveld E, Alonzo TA, Fornerod M, Zimmermann M, Pigazzi M, Pieters R, Meshinchi S, Zwaan CM, Locatelli F. Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia Blood. 126: 2598-2598. DOI: 10.1182/Blood.V126.23.2598.2598 |
0.459 |
|
| 2015 |
Farrar JE, Alonzo TA, Ries RE, Gerbing RB, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Mungall K, Ma Y, Long W, Zong S, Kolb EA, et al. ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative Blood. 126: 2587-2587. DOI: 10.1182/Blood.V126.23.2587.2587 |
0.377 |
|
| 2015 |
Ostronoff F, Alonzo TA, Othus M, Kutny MA, Gerbing RB, Radich JP, Erba HP, Appelbaum FR, Kolb EA, Gamis AS, Stirewalt DL, Meshinchi S. Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106 Blood. 126: 2576-2576. DOI: 10.1182/Blood.V126.23.2576.2576 |
0.387 |
|
| 2015 |
Kutny MA, Alonzo TA, Gerbing RB, Wang Y, Fu C, Meshinchi S, Gamis AS, Feusner JH, Gregory J. Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631 Blood. 126: 219-219. DOI: 10.1182/Blood.V126.23.219.219 |
0.419 |
|
| 2015 |
Maxson JE, Ries R, Wang Y, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong S, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, ... ... Alonzo TA, et al. CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative Blood. 126: 174-174. DOI: 10.1182/Blood.V126.23.174.174 |
0.36 |
|
| 2015 |
Chin D, Kutny MA, Grim J, Gerbing RB, Miller K, Farrar JE, Guidry Auvil JM, Smith MA, Gerhard DS, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Moore R, ... ... Alonzo TA, et al. Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative Blood. 126: 170-170. DOI: 10.1182/Blood.V126.23.170.170 |
0.4 |
|
| 2015 |
Ostronoff F, Ries RE, Gerbing RB, Marra MA, Yussanne M, Long W, Zong S, Mungall K, Andrew A, Gerhard DS, Smith MA, Patee G, Davidsen TM, Hermida LC, Farrar JE, ... ... Alonzo TA, et al. Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative Blood. 126: 169-169. DOI: 10.1182/Blood.V126.23.169.169 |
0.44 |
|
| 2015 |
Voigt AP, Brodersen LE, Gerbing RB, Menssen AJ, Hirsch BA, Raimondi SC, Gamis AS, Alonzo TA, Meshinchi S, Loken MR. Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531 Blood. 126: 1377-1377. DOI: 10.1182/Blood.V126.23.1377.1377 |
0.324 |
|
| 2015 |
Kutny MA, Alonzo TA, Wang Y, Ries R, Farrar JE, Guidry Auvil JM, Smith MA, Gerhard DS, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Moore R, Long W, et al. TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative Blood. 126: 1368-1368. DOI: 10.1182/Blood.V126.23.1368.1368 |
0.397 |
|
| 2015 |
Lamba JK, Chauhan L, Aplenc R, Skrypek M, Pollard J, Alonzo TA, Wang Y, Bernstein ID, Gamis AS, Meshinchi S. Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study Blood. 126: 1260-1260. DOI: 10.1182/Blood.V126.23.1260.1260 |
0.402 |
|
| 2014 |
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 124: 2400-7. PMID 25145343 DOI: 10.1182/Blood-2014-04-570929 |
0.457 |
|
| 2014 |
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3021-32. PMID 25092781 DOI: 10.1200/Jco.2014.55.3628 |
0.415 |
|
| 2014 |
Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 61: 1754-60. PMID 24976003 DOI: 10.1002/Pbc.25117 |
0.425 |
|
| 2014 |
Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 120: 2482-9. PMID 24771494 DOI: 10.1002/Cncr.28674 |
0.408 |
|
| 2014 |
Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. British Journal of Haematology. 166: 254-9. PMID 24661089 DOI: 10.1111/Bjh.12852 |
0.397 |
|
| 2014 |
Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leukemia & Lymphoma. 55: 2817-21. PMID 24559289 DOI: 10.3109/10428194.2014.893305 |
0.388 |
|
| 2014 |
Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, Meshinchi S, Alonzo TA, Gamis A, Aplenc R. Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group. Acta Haematologica. 131: 167-9. PMID 24217778 DOI: 10.1159/000353758 |
0.372 |
|
| 2014 |
Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 61: 647-52. PMID 24127439 DOI: 10.1002/Pbc.24822 |
0.388 |
|
| 2014 |
Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch B, Raimondi SC, Gamis AS, Meshinchi S. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. Pediatric Blood & Cancer. 61: 81-8. PMID 23956224 DOI: 10.1002/Pbc.24700 |
0.349 |
|
| 2014 |
Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W, Lange BJ, Parsons SK, Woods WG. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatric Blood & Cancer. 61: 269-75. PMID 23955900 DOI: 10.1002/Pbc.24739 |
0.351 |
|
| 2014 |
Aplenc R, Fisher B, Li Y, Alonzo TA, Gerbing RB, Hall M, Arnold SD, Huang Y, Seif AE, Bagatell R, Sung L, Adamson PC, Gamis AS, Keren R. Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 32: 7086-7086. DOI: 10.1200/Jco.2014.32.15_Suppl.7086 |
0.374 |
|
| 2014 |
Phillips CL, Lane A, Radloff G, Gerbing RB, Alonzo TA, Lange B, Gamis AS, Hartford CM, Dolan ME, Davies S. Influence of polymorphisms discovered in cell-based model of cytarabine sensitivity on outcome in pediatric AML: A Children's Oncology Group Study. Journal of Clinical Oncology. 32: 10040-10040. DOI: 10.1200/Jco.2014.32.15_Suppl.10040 |
0.369 |
|
| 2014 |
Kutny MA, Alonzo TA, Gerbing RB, Wang Y, Fu C, Meshinchi S, Gamis AS, Feusner JH, Gregory J. Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children’s Oncology Group AAML0631 Trial Blood. 124: 985-985. DOI: 10.1182/Blood.V124.21.985.985 |
0.35 |
|
| 2014 |
Klein K, Kaspers G, Harrison CJ, Beverloo B, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmermann M, Creutzig U, Dworzak M, Alonzo TA, Johnston D, Zapotocky M, et al. Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML Blood. 124: 481-481. DOI: 10.1182/Blood.V124.21.481.481 |
0.423 |
|
| 2014 |
Stieglitz E, Troup CB, Gelston LC, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Emanuel PD, Braun BS, Gerbing RB, Alonzo TA, Loh ML. Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia Blood. 124: 410-410. DOI: 10.1182/Blood.V124.21.410.410 |
0.378 |
|
| 2014 |
Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang Y, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531 Blood. 124: 377-377. DOI: 10.1182/Blood.V124.21.377.377 |
0.315 |
|
| 2014 |
August KJ, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Horan JT, Alonzo TA, Gerbing RB, Wang YJ, Kahwash S, Heerema-McKenney A, Meshinchi S, Gamis AS. Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531 Blood. 124: 3672-3672. DOI: 10.1182/Blood.V124.21.3672.3672 |
0.443 |
|
| 2014 |
Kutny MA, Rajpurkar M, Alonzo TA, Gerbing RB, Gamis AS, Feusner JH, Gregory J. Evaluation of ISTH DIC Score to Predict Significant Bleeding and Thrombosis Events in Pediatric Acute Promyelocytic Leukemia; A Report from the Children’s Oncology Group AAML0631 Trial Blood. 124: 3669-3669. DOI: 10.1182/Blood.V124.21.3669.3669 |
0.39 |
|
| 2014 |
Ramamurthy R, Hughes MD, Bolouri H, Gerbing RB, Wang Y, Loken MR, Raimondi SC, Hirsch BA, Aplenc R, Gamis AS, Alonzo TA, Meshinchi S. Correlation of Mir-155 Expression with Clinical Outcome in Childhood AML: A Report from Children’s Oncology Group Blood. 124: 3545-3545. DOI: 10.1182/Blood.V124.21.3545.3545 |
0.391 |
|
| 2014 |
Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head DR, Raimondi SC, Hirsch BA, Gerbing RB, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial Blood. 124: 278-278. DOI: 10.1182/Blood.V124.21.278.278 |
0.448 |
|
| 2014 |
Johnston D, Rubnitz JE, Alonzo TA, Gerbing RB, Aplenc R, Gamis AS, Meshinchi S. An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Children’s Oncology Group Protocols AAML0531 and 03P1 and St Jude Children’s Research Hospital Protocol AML02 Blood. 124: 277-277. DOI: 10.1182/Blood.V124.21.277.277 |
0.436 |
|
| 2014 |
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang Y, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children’s Oncology Group Blood. 124: 2330-2330. DOI: 10.1182/Blood.V124.21.2330.2330 |
0.43 |
|
| 2014 |
Rao P, Li Y, Alonzo TA, Sung L, Gerbing RB, Getz KD, Seif AE, Miller TP, Huang Y, Bagatell R, Hall M, Fisher BT, Gamis AS, Aplenc R. Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children’s Oncology Group Blood. 124: 2286-2286. DOI: 10.1182/Blood.V124.21.2286.2286 |
0.395 |
|
| 2014 |
Schuback HL, Alonzo TA, Gerbing RB, Miller KL, Kahwash S, Heerema-Mckenney A, Hirsch BA, Raimondi SC, Aplenc R, Gamis AS, Meshinchi S. CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children’s Oncology Group Report Blood. 124: 13-13. DOI: 10.1182/Blood.V124.21.13.13 |
0.436 |
|
| 2013 |
Woods WG, Franklin AR, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD, Larson RA. Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. Cancer. 119: 4170-9. PMID 24104597 DOI: 10.1002/Cncr.28344 |
0.328 |
|
| 2013 |
Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ, Meshinchi S, Woods WG, Perentesis J, Horan J. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer. 119: 4162-9. PMID 24104395 DOI: 10.1002/Cncr.28342 |
0.421 |
|
| 2013 |
Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC. Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 60: 2073-8. PMID 24039149 DOI: 10.1002/Pbc.24573 |
0.396 |
|
| 2013 |
Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Haas V, Mihál V, De Moerloose B, Jeison M, Rubnitz JE, Tomizawa D, Johnston D, Alonzo TA, Hasle H, Auvrignon A, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. Blood. 122: 2704-13. PMID 23974201 DOI: 10.1182/Blood-2013-02-485524 |
0.384 |
|
| 2013 |
Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. British Journal of Haematology. 162: 670-7. PMID 23826732 DOI: 10.1111/Bjh.12444 |
0.463 |
|
| 2013 |
Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, W McIntosh M, Meshinchi S. Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. American Journal of Hematology. 88: 694-702. PMID 23686445 DOI: 10.1002/Ajh.23486 |
0.435 |
|
| 2013 |
Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, et al. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. British Journal of Haematology. 162: 250-62. PMID 23682827 DOI: 10.1111/Bjh.12370 |
0.386 |
|
| 2013 |
de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia. 27: 2280-8. PMID 23531517 DOI: 10.1038/Leu.2013.87 |
0.414 |
|
| 2013 |
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood. 121: 3573-7. PMID 23471307 DOI: 10.1182/Blood-2013-01-476614 |
0.335 |
|
| 2013 |
Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, et al. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1620-7. PMID 23444229 DOI: 10.1158/1078-0432.Ccr-12-3115 |
0.358 |
|
| 2013 |
Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. British Journal of Haematology. 161: 192-203. PMID 23398482 DOI: 10.1111/Bjh.12233 |
0.327 |
|
| 2013 |
Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediatric Blood & Cancer. 60: 1141-7. PMID 23335239 DOI: 10.1002/Pbc.24398 |
0.393 |
|
| 2013 |
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S. Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. Pediatric Blood & Cancer. 60: 964-71. PMID 23255301 DOI: 10.1002/Pbc.24432 |
0.433 |
|
| 2013 |
Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, Meshinchi S. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood. 121: 1083-93. PMID 23243289 DOI: 10.1182/Blood-2012-04-421925 |
0.348 |
|
| 2013 |
Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB. High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leukemia & Lymphoma. 54: 202-4. PMID 22680764 DOI: 10.3109/10428194.2012.700480 |
0.469 |
|
| 2013 |
Miller TP, Kavcic M, Li Y, Alonzo TA, Hall M, Huang Y, Gerbing RB, Fisher BT, Luger S, Rubin D, Troxel A, Sung L, Gamis AS, Aplenc R. Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group Blood. 122: 931-931. DOI: 10.1182/Blood.V122.21.931.931 |
0.421 |
|
| 2013 |
Horan JT, Meshinchi S, Loken MR, Alonzo TA, Aplenc R, Davies SM, Gerbing RB, Gamis AS. Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission Blood. 122: 65-65. DOI: 10.1182/Blood.V122.21.65.65 |
0.436 |
|
| 2013 |
Alonzo TA, Gerbing RB, Kahwash S, Heerema-McKenney A, Aplenc R, Sung L, Winter L, Glick K, Ccrp, Davies SM, Byron P, Lavey RS, Smith FO, Ho PA, Gamis AS, et al. Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report Blood. 122: 612-612. DOI: 10.1182/Blood.V122.21.612.612 |
0.404 |
|
| 2013 |
Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Alonzo TA, Gerbing RB, Gamis AS, Meshinchi S, Aplenc R. Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group Blood. 122: 610-610. DOI: 10.1182/Blood.V122.21.610.610 |
0.389 |
|
| 2013 |
Pollard J, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch B, Aplenc R, Gamis AS, Loken MR, Meshinchi S. Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group Blood. 122: 491-491. DOI: 10.1182/Blood.V122.21.491.491 |
0.379 |
|
| 2013 |
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG Blood. 122: 488-488. DOI: 10.1182/Blood.V122.21.488.488 |
0.465 |
|
| 2013 |
Aplenc R, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi SC, Hirsch B, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Ccrp, Davies SM, Byron P, Smith FO. Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531 Blood. 122: 355-355. DOI: 10.1182/Blood.V122.21.355.355 |
0.435 |
|
| 2013 |
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Meshinchi S, Gamis AS. Duration Of Neutropenia Is Associated With Reduced Relapse Risk In Children With De Novo Acute Myeloid Leukemia: A Report From The Children’s Oncology Group Blood. 122: 2650-2650. DOI: 10.1182/Blood.V122.21.2650.2650 |
0.424 |
|
| 2013 |
Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch B, Kahwash S, Heerema-McKenney A, Gamis AS, Meshinchi S. Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group Blood. 122: 2609-2609. DOI: 10.1182/Blood.V122.21.2609.2609 |
0.372 |
|
| 2013 |
Kuhn J, Meerzaman D, Ries RE, Milano F, Gamis AS, Alonzo TA, Guidry-Auvil J, Davidsen TM, Smith MA, Chunhua Y, Hsu CH, Nguyen C, Gerhard DS, Wai D, Arceci RJ, et al. PIM3-SCO2 Fusion Is a Novel Transcription-Induced Chimera That Is Highly Prevalent In Childhood AML Blood. 122: 2549-2549. DOI: 10.1182/Blood.V122.21.2549.2549 |
0.335 |
|
| 2013 |
Gramatges MM, Sasa GS, Gerbing RB, Jo E, Alonzo TA, Ahern CH, Meshinchi S, Bertuch AA. Constitutional Telomerase-Associated Gene Variants In Pediatric Acute Myeloid Leukemia (AML) and In Association With Chemotherapy-Related Toxicities Blood. 122: 1310-1310. DOI: 10.1182/Blood.V122.21.1310.1310 |
0.384 |
|
| 2013 |
Mast K, Taub J, Alonzo T, Mosse C, Gamis A, Mathew P, Jones H, Hitzler J, Head D. P-148 Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in Down syndrome: Pathologic aspects Leukemia Research. 37: S89-S90. DOI: 10.1016/S0145-2126(13)70196-6 |
0.312 |
|
| 2012 |
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 97: 1770-3. PMID 22801969 DOI: 10.3324/Haematol.2012.065490 |
0.38 |
|
| 2012 |
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 120: 1581-8. PMID 22649108 DOI: 10.1182/Blood-2012-02-408336 |
0.46 |
|
| 2012 |
Aplenc R, Fisher BT, Huang YS, Li Y, Alonzo TA, Gerbing RB, Hall M, Bertoch D, Keren R, Seif AE, Sung L, Adamson PC, Gamis A. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiology and Drug Safety. 21: 37-43. PMID 22552978 DOI: 10.1002/Pds.3241 |
0.351 |
|
| 2012 |
Rochowski A, Olson SB, Alonzo TA, Gerbing RB, Lange BJ, Alter BP. Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML. Pediatric Blood & Cancer. 59: 922-4. PMID 22517793 DOI: 10.1002/Pbc.24168 |
0.329 |
|
| 2012 |
Chaleff S, Hurwitz CA, Chang M, Dahl G, Alonzo TA, Weinstein H. Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: A Paediatric Oncology Group study British Journal of Haematology. 156: 649-655. PMID 22512017 DOI: 10.1111/J.1365-2141.2011.08976.X |
0.418 |
|
| 2012 |
Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 118: 4806-14. PMID 22392565 DOI: 10.1002/Cncr.27484 |
0.378 |
|
| 2012 |
Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 119: 3705-11. PMID 22378848 DOI: 10.1182/Blood-2011-12-398370 |
0.384 |
|
| 2012 |
Sung L, Buxton A, Gamis A, Woods WG, Alonzo TA. Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Journal of Pediatric Hematology/Oncology. 34: e30-5. PMID 22052170 DOI: 10.1097/Mph.0B013E31822817A6 |
0.36 |
|
| 2012 |
Rochowski A, Rosenberg PS, Alonzo TA, Gerbing RB, Lange BJ, Alter BP. Estimation of the prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia who have poor recovery from chemotherapy. Leukemia Research. 36: 29-31. PMID 21974856 DOI: 10.1016/J.Leukres.2011.09.009 |
0.4 |
|
| 2012 |
Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 118: 761-9. PMID 21766293 DOI: 10.1002/Cncr.26190 |
0.386 |
|
| 2012 |
Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 58: 519-24. PMID 21618422 DOI: 10.1002/Pbc.23201 |
0.385 |
|
| 2012 |
Reedijk A, Kaspers G, Fiocco M, Pession A, Reinhardt D, Zimmermann M, Dworzak M, Alonzo TA, Johnston D, Zapotocky M, De Moerloose B, Finita F, Lee V, Taga T, Tawa A, et al. Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study Blood. 120: 884-884. DOI: 10.1182/Blood.V120.21.884.884 |
0.395 |
|
| 2012 |
de Rooij JD, van den Heuvel-Eibrink MM, Hollink IH, Arentsen-Peters ST, Beverloo HB, van Galen JF, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, Zwaan CM. NUP98/JARID1A Is a New Recurrent Genetic Abnormality in Pediatric Acute Megakaryoblastic Leukemia with a Distinct HOX-Gene Expression Pattern Blood. 120: 537-537. DOI: 10.1182/Blood.V120.21.537.537 |
0.409 |
|
| 2012 |
Ostronoff F, Alonzo TA, Gerbing RB, Loken MR, Pardo L, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Lavey RS, et al. Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group Blood. 120: 529-529. DOI: 10.1182/Blood.V120.21.529.529 |
0.443 |
|
| 2012 |
Horton TM, Perentesis J, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard D, Smith FO, Moscow JA. A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study Blood. 120: 3580-3580. DOI: 10.1182/Blood.V120.21.3580.3580 |
0.4 |
|
| 2012 |
Bolouri H, Ries RE, Ramamurthy R, Alonzo TA, Auvil JMG, Davidsen TM, Gesuwan P, Gamis AS, Smith MA, Gerhard DS, Arceci RJ, Meshinchi S. Integrative Network Analysis of Pediatric AML Whole Genomes, cDNA Expression and Clinical Data Elements Reveals Shared As Well As t(8;21), Inv16 and MLL Specific Pathways; A Report From COG/NCI Target AML Initiative Blood. 120: 3519-3519. DOI: 10.1182/Blood.V120.21.3519.3519 |
0.351 |
|
| 2012 |
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Raimondi SC, Hirsch BA, Franklin J, Gamis AS, Meshinchi S. Elevated BAALC Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children's Oncology Group. Blood. 120: 2553-2553. DOI: 10.1182/Blood.V120.21.2553.2553 |
0.441 |
|
| 2012 |
Stirewalt DL, Alonzo TA, Pogosova-Agadjanyan EL, Gerbing RB, Franklin J, Lee H, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML. Blood. 120: 2550-2550. DOI: 10.1182/Blood.V120.21.2550.2550 |
0.45 |
|
| 2012 |
Stirewalt DL, Alonzo TA, Pogosova-Agadjanyan EL, Gerbing RB, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML. Blood. 120: 2546-2546. DOI: 10.1182/Blood.V120.21.2546.2546 |
0.448 |
|
| 2012 |
Moraleda PP, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S. Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group. Blood. 120: 2541-2541. DOI: 10.1182/Blood.V120.21.2541.2541 |
0.461 |
|
| 2012 |
Ho PA, Alonzo T, Gerbing RB, Pollard JA, Raimondi SC, Hirsch BA, Cooper T, Gamis AS, Meshinchi S. High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group. Blood. 120: 2530-2530. DOI: 10.1182/Blood.V120.21.2530.2530 |
0.448 |
|
| 2012 |
Ramamurthy R, Alonzo TA, Gerbing RB, Loken MR, Pardo L, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Francisco LE, et al. Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group. Blood. 120: 2388-2388. DOI: 10.1182/Blood.V120.21.2388.2388 |
0.319 |
|
| 2012 |
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of Supportive Care Measurements to Reduce Infections During Induction for Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group Blood. 120: 1478-1478. DOI: 10.1182/Blood.V120.21.1478.1478 |
0.35 |
|
| 2012 |
Kutny MA, Alonzo TA, Gerbing RB, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group Blood. 120: 1425-1425. DOI: 10.1182/Blood.V120.21.1425.1425 |
0.39 |
|
| 2012 |
Johnston DL, Alonzo TA, Gerbing RB, Hirsch BA, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC. Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q-Abnormalities Enrolled On Five Children's Oncology Group Acute Myeloid Leukemia Treatment Protocols Blood. 120: 1414-1414. DOI: 10.1182/Blood.V120.21.1414.1414 |
0.422 |
|
| 2012 |
Gramatges MM, Alonzo TA, Gerbing RB, Bertuch AA, Meshinchi S. Constitutional Telomerase-Associated Gene Variants Associated with Chemotherapy-Related Toxicities in Pediatric Acute Myeloid Leukemia (AML) Blood. 120: 1403-1403. DOI: 10.1182/Blood.V120.21.1403.1403 |
0.381 |
|
| 2012 |
Ho PA, Alonzo TA, Gerbing RB, Sung L, Aplenc R, Pollard JA, Kuhn J, Heerema NA, Lange BJ, Gamis AS, Meshinchi S. WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group Blood. 120: 1385-1385. DOI: 10.1182/Blood.V120.21.1385.1385 |
0.394 |
|
| 2012 |
Ochs M, Farrar J, Considine M, Ries RE, Trevino LR, Alonzo TA, Guidry-Auvil J, Davidsen TM, Gesuwan P, Muzny DM, Gamis AS, Wheeler DA, Helton HL, Smith MA, Gerhard DS, et al. Genome Wide Promoter Methylation Patterns Predict AML Subtype Outcomes and Identify Novel Pathways Characterizing Diagnostic and Relapsed Disease in Children Blood. 120: 1287-1287. DOI: 10.1182/Blood.V120.21.1287.1287 |
0.371 |
|
| 2012 |
Ostronoff F, Fitzgibbon M, McIntosh M, Ries RE, Gamis AS, Alonzo TA, Appelbaum FR, Stirewalt DL, Meshinchi S. RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia Blood. 120: 1278-1278. DOI: 10.1182/Blood.V120.21.1278.1278 |
0.363 |
|
| 2012 |
Kelly MJ, Horan JT, Alonzo TA, Eapen M, Gerbing RB, He W, Lange BJ, Parsons SK, Woods WG. Hematopoietic Cell Transplant Versus Chemotherapy As Consolidation Treatment for Pediatric AML with Poor-Risk Cytogenetics Blood. 120: 127-127. DOI: 10.1182/Blood.V120.21.127.127 |
0.412 |
|
| 2012 |
Helton HL, Ries RE, Alonzo TA, Gerbing RB, Trevino LR, Farrar J, Auvil JMG, Davidsen TM, Gesuwan P, Muzny DM, Gamis AS, Franklin J, Wheeler DA, Smith MA, Gerhard DS, et al. Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative Blood. 120: 125-125. DOI: 10.1182/Blood.V120.21.125.125 |
0.452 |
|
| 2012 |
Meshinchi S, Ries RE, Trevino LR, Hampton OA, Alonzo T, Farrar JE, Auvil JMG, Davidsen TM, Gesuwan P, Muzny DM, Gamis AS, Helton HL, Wheeler DA, Smith MA, Gerhard DS, et al. Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study Blood. 120: 123-123. DOI: 10.1182/Blood.V120.21.123.123 |
0.376 |
|
| 2012 |
Meshinchi S, Ries RE, Farrar J, Auvil JG, Davidsen TM, Gesuwan P, Trevino LR, Muzny DM, Wheeler DA, Gamis AS, Alonzo TA, Smith MA, Gerhard DS, Arceci RJ. Abstract LB-93: Demonstration of significant clonal evolution from diagnosis to relapse in childhood AML determined by exome capture sequencing: an NCI/COG TARGET AML study Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-93 |
0.38 |
|
| 2011 |
Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 118: 4561-6. PMID 21873548 DOI: 10.1182/Blood-2011-04-348888 |
0.37 |
|
| 2011 |
Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 118: 6752-9; quiz 6996. PMID 21849481 DOI: 10.1182/Blood-2011-04-350017 |
0.361 |
|
| 2011 |
Mathew P, Gerbing R, Alonzo TA, Wallas T, Gong JZ, Jasty R, Jorstad DT, Raimondi SC, Chavez CM, Eisenberg NL, Hirsch B, Gamis A, Smith FO, Arceci RJ. A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121). Pediatric Blood & Cancer. 57: 1230-2. PMID 21681928 DOI: 10.1002/Pbc.23164 |
0.398 |
|
| 2011 |
Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatric Blood & Cancer. 57: 398-405. PMID 21681921 DOI: 10.1002/Pbc.22966 |
0.331 |
|
| 2011 |
Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood. 117: 7102-11. PMID 21551233 DOI: 10.1182/Blood-2010-12-328302 |
0.405 |
|
| 2011 |
Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 117: 7007-13. PMID 21518931 DOI: 10.1182/Blood-2011-02-337725 |
0.349 |
|
| 2011 |
Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 57: 204-9. PMID 21504050 DOI: 10.1002/Pbc.23179 |
0.339 |
|
| 2011 |
Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerema NA, Oehler V, Wood C, French ME, Arceci RJ, Smith FO, Bernstein ML. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 57: 56-62. PMID 21465636 DOI: 10.1002/Pbc.23031 |
0.326 |
|
| 2011 |
Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 117: 5701-9. PMID 21447830 DOI: 10.1182/Blood-2010-04-280123 |
0.325 |
|
| 2011 |
Berman JN, Gerbing RB, Alonzo TA, Ho PA, Miller K, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Gamis A, Meshinchi S. Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia. 25: 1039-42. PMID 21358716 DOI: 10.1182/Blood.V114.22.3115.3115 |
0.429 |
|
| 2011 |
Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, Meshinchi S. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 704-11. PMID 21189390 DOI: 10.1200/Jco.2010.31.9327 |
0.345 |
|
| 2011 |
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, et al. Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531 Blood. 118: 939-939. DOI: 10.1182/Blood.V118.21.939.939 |
0.437 |
|
| 2011 |
Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange B, Tweardy DJ, Meshinchi S. FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report Blood. 118: 938-938. DOI: 10.1182/Blood.V118.21.938.938 |
0.331 |
|
| 2011 |
Kutny MA, Alonzo TA, Gerbing RB, Geraghty D, Gamis AS, Lange B, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Meshinchi S. TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group Blood. 118: 569-569. DOI: 10.1182/Blood.V118.21.569.569 |
0.423 |
|
| 2011 |
Moore AS, Alonzo TA, Gerbing RB, Lange B, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group, Blood. 118: 3555-3555. DOI: 10.1182/Blood.V118.21.3555.3555 |
0.429 |
|
| 2011 |
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, et al. Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group, Blood. 118: 3545-3545. DOI: 10.1182/Blood.V118.21.3545.3545 |
0.44 |
|
| 2011 |
Lacayo NJ, Alonzo TA, Gayko U, Westfall M, Purvis N, Putta S, Hackett J, Cohen AC, Gerbing RB, Dahl GV, Gamis AS, Meshinchi S. Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results, Blood. 118: 3544-3544. DOI: 10.1182/Blood.V118.21.3544.3544 |
0.429 |
|
| 2011 |
Lamba J, Mortland LJ, Mitra A, Walter RB, Pollard JA, Alonzo TA, Gerbing RB, Hirsch BA, Raimondi SC, Franklin J, Meshinchi S. Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy, Blood. 118: 3489-3489. DOI: 10.1182/Blood.V118.21.3489.3489 |
0.362 |
|
| 2011 |
Aplenc R, Fisher BT, Sung L, Keren R, Alonzo TA, Hall M, Huang YV, Li Y, Luan X, Gerbing RB, Bertoch D, Seif AE, Adamson PC, Gamis AS. Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group Blood. 118: 2617-2617. DOI: 10.1182/Blood.V118.21.2617.2617 |
0.369 |
|
| 2011 |
Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch BA, Raimondi SC, Gamis AS, Meshinchi S. The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children's Oncology Group (COG) Blood. 118: 1444-1444. DOI: 10.1182/Blood.V118.21.1444.1444 |
0.41 |
|
| 2011 |
Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Tweardy DJ. Abstract 2908: Multiparameter FACS analysis of Stat3 and Stat5 signaling in pediatric AML samples Cancer Research. 71: 2908-2908. DOI: 10.1158/1538-7445.Am2011-2908 |
0.352 |
|
| 2010 |
Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatric Blood & Cancer. 55: 414-20. PMID 20658610 DOI: 10.1002/Pbc.22511 |
0.394 |
|
| 2010 |
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 55: 248-53. PMID 20582981 DOI: 10.1002/Pbc.22519 |
0.33 |
|
| 2010 |
Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2831-8. PMID 20421533 DOI: 10.1200/Jco.2009.27.5693 |
0.397 |
|
| 2010 |
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Meshinchi S. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 116: 702-10. PMID 20413658 DOI: 10.1182/Blood-2010-02-268953 |
0.415 |
|
| 2010 |
Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia. 24: 909-13. PMID 20376086 DOI: 10.1038/Leu.2010.56 |
0.406 |
|
| 2010 |
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 115: 2372-9. PMID 20056794 DOI: 10.1182/Blood-2009-09-241075 |
0.412 |
|
| 2010 |
Lacayo NJ, Cohen A, Westfall M, Lackey A, Xin X(, Gayko U, Putta S, Meshinchi S, Raimondi SC, Alonzo TA, Arceci RJ, Ravindranath Y, Dahl GVH, Cesano A. Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421 Blood. 116: 954-954. DOI: 10.1182/Blood.V116.21.954.954 |
0.398 |
|
| 2010 |
Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin J, Lange B, Gamis AS, Alonzo TA, Meshinchi S. The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group Blood. 116: 950-950. DOI: 10.1182/Blood.V116.21.950.950 |
0.38 |
|
| 2010 |
Kutny MA, Alonzo TA, Gerbing RB, Ho PA, Geraghty D, Lange B, Heerema NA, Meshinchi S. TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group Blood. 116: 949-949. DOI: 10.1182/Blood.V116.21.949.949 |
0.377 |
|
| 2010 |
Coenen EA, Raimondi SC, Harbott J, Martin Z, Balgobind BV, Alonzo TA, Auvrignon A, Beverloo B, Chang M, Creutzig U, Dworzak M, Forestier E, Gibson B, Hasle H, Harrison CJ, et al. Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study Blood. 116: 762-762. DOI: 10.1182/Blood.V116.21.762.762 |
0.416 |
|
| 2010 |
Alonzo TA, Ho PA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Cooper T, Franklin J, Pardo L, Loken MR, Meshinchi S. Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group Blood. 116: 761-761. DOI: 10.1182/Blood.V116.21.761.761 |
0.416 |
|
| 2010 |
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, et al. Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531 Blood. 116: 2740-2740. DOI: 10.1182/Blood.V116.21.2740.2740 |
0.361 |
|
| 2010 |
Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Ries RE, Gerbing RB, Fan W, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin J, Gamis AS, et al. Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study Blood. 116: 2737-2737. DOI: 10.1182/Blood.V116.21.2737.2737 |
0.38 |
|
| 2010 |
Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Ries R, Zeng R, Miller KL, Kuhn J, Raimondi SC, Hirsch BA, Franklin J, Gamis AS, Loken MR, Meshinchi S. Association of CD33 Expression Level with Disease Risk-Group Classification and Induction Response In Pediatric AML: A Report From the Children's Oncology Group Blood. 116: 2732-2732. DOI: 10.1182/Blood.V116.21.2732.2732 |
0.361 |
|
| 2010 |
Rochowski A, Rosenberg PS, Alonzo TA, Gerbing RB, Lange B, Alter BP. The Prevalence of Fanconi Anemia Among Patients with De Novo Acute Myelogenous Leukemia Blood. 116: 2232-2232. DOI: 10.1182/Blood.V116.21.2232.2232 |
0.428 |
|
| 2010 |
Franklin AR, Alonzo TA, Gerbing RB, Donohue K, Othus M, Horan J, Estey EH, Larson RA, Woods WG. Outcome of Adolescents and Young Adults (AYAs) with Non-M3 Acute Myeloid Leukemia (AML) Treated on Children's Oncology Group (COG) Trials Compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) Trials Blood. 116: 183-183. DOI: 10.1182/Blood.V116.21.183.183 |
0.417 |
|
| 2010 |
Gamis AS, Alonzo TA, Gerbing RB, Aplenc R, Sung L, Meshinchi S, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, et al. Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531 Blood. 116: 182-182. DOI: 10.1182/Blood.V116.21.182.182 |
0.357 |
|
| 2010 |
Meshinchi S, Alonzo TA, Gerbing RB, Ho PA, Gamis AS, Raimondi SC, Hirsch BA, Cooper T, Franklin J, Pardo L, Loken MR. Identification of Post-Induction Minimal Residual Disease by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse and Poor Outcome- a Report From the Children's Oncology Group Blood. 116: 1702-1702. DOI: 10.1182/Blood.V116.21.1702.1702 |
0.436 |
|
| 2010 |
Pope JM, Kim M, Alonzo TA, Gerbing RB, Rayburg M, Radloff G, Gamis AS, Davies SM, Perentesis J. Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome. Blood. 116: 1680-1680. DOI: 10.1182/Blood.V116.21.1680.1680 |
0.343 |
|
| 2010 |
Kutny MA, Miller K, Alonzo TA, Gerbing RB, Ho PA, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S. CBL Mutations In Pediatric Acute Myelogenous Leukemia Are a Rare Event, a Report From the Children's Oncology Group. Blood. 116: 1659-1659. DOI: 10.1182/Blood.V116.21.1659.1659 |
0.362 |
|
| 2010 |
Sung L, Alonzo TA, Gerbing RB, Aplenc R, Meshinchi S, Burden L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, et al. High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood. 116: 1072-1072. DOI: 10.1182/Blood.V116.21.1072.1072 |
0.39 |
|
| 2010 |
Sung L, Aplenc R, Alonzo TA, Gerbing RB, Meshinchi S, Burden L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, et al. Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group. Blood. 116: 1071-1071. DOI: 10.1182/Blood.V116.21.1071.1071 |
0.37 |
|
| 2010 |
Redell MS, Ruiz MJ, Alonzo T, Tweardy DJ. Abstract 1791: Stat3 signaling in acute myeloid leukemia: Ligand-dependent and -independent activation, impact on prognosis, and induction of apoptosis by a novel Stat3 inhibitor Cancer Research. 70: 1791-1791. DOI: 10.1158/1538-7445.Am10-1791 |
0.356 |
|
| 2009 |
Shaw PA, Pepe MS, Alonzo TA, Etzioni R. Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test. Statistics in Biopharmaceutical Research. 1: 18-25. PMID 20054437 DOI: 10.1198/Sbr.2009.0002 |
0.546 |
|
| 2009 |
Gregory J, Kim H, Alonzo T, Gerbing R, Woods W, Weinstein H, Shepherd L, Schiffer C, Appelbaum F, Willman C, Wiernik P, Rowe J, Tallman M, Feusner J. Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. Pediatric Blood & Cancer. 53: 1005-10. PMID 19743516 DOI: 10.1002/Pbc.22165 |
0.406 |
|
| 2009 |
Noronha SA, Farrar JE, Alonzo TA, Gerbing RB, Lacayo NJ, Dahl GV, Ravindranath Y, Arceci RJ, Loeb DM. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 53: 1136-9. PMID 19618455 DOI: 10.1002/Pbc.22142 |
0.411 |
|
| 2009 |
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 114: 2489-96. PMID 19528532 DOI: 10.1182/Blood-2009-04-215152 |
0.362 |
|
| 2009 |
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich JP, Meshinchi S. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 113: 6558-66. PMID 19304957 DOI: 10.1182/Blood-2008-10-184747 |
0.388 |
|
| 2009 |
Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J, Woods WG. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 115: 1100-8. PMID 19156894 DOI: 10.1002/Cncr.24107 |
0.353 |
|
| 2009 |
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. British Journal of Haematology. 144: 388-94. PMID 19036079 DOI: 10.1111/J.1365-2141.2008.07461.X |
0.386 |
|
| 2009 |
Cooper T, Alonzo TA, Gerbing RB, Perentesis J, Whitlock JA, Raetz E, Carroll WL, Gamis AS, Razzouk BI. AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia. Blood. 114: 3076-3076. DOI: 10.1182/Blood.V114.22.3076.3076 |
0.381 |
|
| 2009 |
Kutny MA, Alonzo TA, Gerbing RB, Miller K, Ho P, Heerema NA, Lange B, Gamis AS, Meshinchi S. RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group. Blood. 114: 2614-2614. DOI: 10.1182/Blood.V114.22.2614.2614 |
0.388 |
|
| 2009 |
Myers KC, Gerbing RB, Alonzo TA, Phillips CL, Gamis AS, Radloff GA, Perentesis J, Davies SM. Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia. Blood. 114: 2610-2610. DOI: 10.1182/Blood.V114.22.2610.2610 |
0.4 |
|
| 2009 |
Walter WB, Alonzo TA, Gerbing RB, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S. High Expression of the Very Late Antigen (VLA)-4 (CD49d) Integrin Predicts for Reduced Risk of Relapse and Better Outcome in Pediatric Acute Myeloid Leukemia (AML): A Report From the Children's Oncology Group. Blood. 114: 1592-1592. DOI: 10.1182/Blood.V114.22.1592.1592 |
0.455 |
|
| 2008 |
Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7896-9. PMID 19047119 DOI: 10.1158/1078-0432.Ccr-08-0418 |
0.353 |
|
| 2008 |
Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, Feusner J, Franklin J, Patterson MJ, Gamis AS. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 51: 784-6. PMID 18680152 DOI: 10.1002/Pbc.21710 |
0.336 |
|
| 2008 |
Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, Bernstein I, Buckley P, Krimmel K, Smith FO, Sievers EL, Arceci RJ. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2390-3295. PMID 18467731 DOI: 10.1200/Jco.2007.13.0096 |
0.379 |
|
| 2008 |
Meshinchi S, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP. Structural and numerical variation of FLT3/ITD in pediatric AML. Blood. 111: 4930-3. PMID 18305215 DOI: 10.1182/Blood-2008-01-117770 |
0.382 |
|
| 2008 |
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: A report from the Children's Oncology Group Leukemia. 22: 265-272. PMID 18033323 DOI: 10.1038/Sj.Leu.2405000 |
0.386 |
|
| 2008 |
Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, ... Alonzo TA, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 111: 1044-53. PMID 18000167 DOI: 10.1182/Blood-2007-04-084293 |
0.43 |
|
| 2008 |
Castellino SM, Alonzo TA, Buxton A, Gold S, Lange BJ, Woods WG. Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatric Blood & Cancer. 50: 9-16. PMID 17252564 DOI: 10.1002/Pbc.21123 |
0.368 |
|
| 2008 |
Johnston D, Alonzo T, Gerbing R, Lange B, Woods WG. Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome. Blood. 112: 920-920. DOI: 10.1182/Blood.V112.11.920.920 |
0.411 |
|
| 2008 |
Rayburg MS, Kim M, Alonzo T, Gerbing R, Radloff GA, Davies SM, Gamis A, Perentesis J. Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome Blood. 112: 2947-2947. DOI: 10.1182/Blood.V112.11.2947.2947 |
0.351 |
|
| 2008 |
Zhang AY, Robinson BW, Kao K, Behling K, Devidas M, Alonzo T, Raimondi SC, Carroll A, Arceci RJ, Gamis A, Hunger SP, Reaman GH, Harvey RC, Willman CL, Wang L, et al. Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants. Blood. 112: 2255-2255. DOI: 10.1182/Blood.V112.11.2255.2255 |
0.322 |
|
| 2008 |
Brown P, Alonzo T, Gerbing R, McIntyre E, Lange B, Small D, Meshinchi S. High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children’s Oncology Group Study Blood. 112: 147-147. DOI: 10.1182/Blood.V112.11.147.147 |
0.424 |
|
| 2008 |
Franklin J, Alonzo T, Hurwitz CA, Gerbing R, Smith F, Arceci RJ, Feusner J, Mathew P, Iannone R, Meshinchi S, Lavey R, Wallace JD, Anderson K, Winter L, Glick K, et al. COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML) Blood. 112: 136-136. DOI: 10.1182/Blood.V112.11.136.136 |
0.418 |
|
| 2007 |
Alonzo TA, Pepe MS. Development and evaluation of classifiers. Methods in Molecular Biology (Clifton, N.J.). 404: 89-116. PMID 18450047 DOI: 10.1007/978-1-59745-530-5_6 |
0.54 |
|
| 2007 |
Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 110: 3532-9. PMID 17660380 DOI: 10.1182/Blood-2007-05-091942 |
0.318 |
|
| 2007 |
Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton A, Buckley JD, Howells W, Gold S, Barnard DR, DeSwarte J, Kalousek D, Lange BJ, Woods WG. Autologous bone marrow transplantation for children with AML in first remission Bone Marrow Transplantation. 40: 313-318. PMID 17563741 DOI: 10.1038/Sj.Bmt.1705680 |
0.396 |
|
| 2007 |
Sposto R, London WB, Alonzo TA. Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2070-7. PMID 17513812 DOI: 10.1200/Jco.2006.09.1983 |
0.383 |
|
| 2007 |
Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D. The incidence and clinical significance of nucleophosmin mutations in childhood AML Blood. 110: 979-985. PMID 17440048 DOI: 10.1182/Blood-2007-02-076604 |
0.44 |
|
| 2007 |
Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 109: 4641-7. PMID 17299091 DOI: 10.1182/Blood-2006-10-051342 |
0.355 |
|
| 2007 |
Barbaric D, Alonzo TA, Gerbing RB, Meshinchi S, Heerema NA, Barnard DR, Lange BJ, Woods WG, Arceci RJ, Smith FO. Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood. 109: 2314-21. PMID 17158236 DOI: 10.1182/Blood-2005-11-025536 |
0.39 |
|
| 2007 |
Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group. Pediatric Blood & Cancer. 49: 17-22. PMID 16856158 DOI: 10.1002/Pbc.20951 |
0.301 |
|
| 2007 |
Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The Presence of Central Nervous System Disease at Diagnosis in Pediatric Acute Myeloid Leukemia Does Not Affect Outcome. Blood. 110: 1827-1827. DOI: 10.1182/Blood.V110.11.1827.1827 |
0.421 |
|
| 2007 |
George A, Alonzo TA, Gerbing RB, Meshinchi S, Ross JA, Perentesis JP, Davies SM. Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML. Blood. 110: 1444-1444. DOI: 10.1182/Blood.V110.11.1444.1444 |
0.388 |
|
| 2007 |
Pollard J, Alonzo T, Gerbing R, Zeng R, Hirsch B, Raimondi S, Heerema N, Woods W, Lange B, Hurwitz C, Arceci R, Radich J, Bernstein I, Heinrich M, Meshinchi S. Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols. Blood. 110: 1442-1442. DOI: 10.1182/Blood.V110.11.1442.1442 |
0.355 |
|
| 2007 |
Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Heerema NA, Lange B, Radich J, Meshinchi S. Prevalence and Prognostic Implications of CEBPα Mutations in Pediatric AML. Blood. 110: 1441-1441. DOI: 10.1182/Blood.V110.11.1441.1441 |
0.352 |
|
| 2007 |
Meshinchi S, Alonzo T, Gerbing RB, Pollard JA, Gamis AS, Hurwitz CA, Franklin JL, Pardo L, Loken M. Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse. Blood. 110: 1429-1429. DOI: 10.1182/Blood.V110.11.1429.1429 |
0.416 |
|
| 2006 |
Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJL, Heerema NA, Gerbing R, Lange BJ, Radich JP. Clinical implications of FLT3 mutations in pediatric AML Blood. 108: 3654-3661. PMID 16912228 DOI: 10.1182/Blood-2006-03-009233 |
0.405 |
|
| 2006 |
Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 20: 1295-7. PMID 16628187 DOI: 10.1038/Sj.Leu.2404233 |
0.367 |
|
| 2006 |
Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 108: 74-80. PMID 16537811 DOI: 10.1182/Blood-2005-10-4004 |
0.373 |
|
| 2006 |
Brumback LC, Pepe MS, Alonzo TA. Using the ROC curve for gauging treatment effect in clinical trials. Statistics in Medicine. 25: 575-90. PMID 16220481 DOI: 10.1002/Sim.2345 |
0.552 |
|
| 2006 |
Mehta PA, Alonzo TA, Gerbing RB, Elliott JS, Wilke TA, Kennedy RJ, Ross JA, Perentesis JP, Lange BJ, Davies SM. XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: A Children's Oncology Group report Blood. 107: 39-45. PMID 16150943 DOI: 10.1182/Blood-2005-06-2305 |
0.43 |
|
| 2006 |
Sharma M, Alonzo TA, Sorrell A, Gerbing RB, Hilden JM, Arceci RJ, Massey G, Doyle JJ, Bayer L, Perentesis JP, Ross J, Smith FO, Brynes R, Hussong J, Hathaway L, et al. Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971. Blood. 108: 376-376. DOI: 10.1182/Blood.V108.11.376.376 |
0.334 |
|
| 2006 |
Brown P, McIntyre E, Rau R, Alonzo TA, Gerbing R, Meshinchi S, Lacayo N, Chang M, Arceci R, Small D. Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study. Blood. 108: 221-221. DOI: 10.1182/Blood.V108.11.221.221 |
0.446 |
|
| 2006 |
Bhatla D, Gerbing RB, Conner HD, Alonzo TA, Zhai X, Mehta P, Ross JA, Geiger H, Lange BJ, Perentesis JP, Davies SM. Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML. Blood. 108: 17-17. DOI: 10.1182/Blood.V108.11.17.17 |
0.354 |
|
| 2006 |
Gamis AS, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, McGavran L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci R. Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971. Blood. 108: 15-15. DOI: 10.1182/Blood.V108.11.15.15 |
0.4 |
|
| 2005 |
Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9172-8. PMID 16361619 DOI: 10.1200/Jco.2005.02.7482 |
0.355 |
|
| 2005 |
Alonzo TA. Standards for reporting prognostic tumor marker studies Journal of Clinical Oncology. 23: 9053-9054. PMID 16301590 DOI: 10.1200/Jco.2005.04.3778 |
0.345 |
|
| 2005 |
Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: A report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 Leukemia. 19: 2054-2062. PMID 16136168 DOI: 10.1038/Sj.Leu.2403925 |
0.441 |
|
| 2005 |
Alonzo TA, Wells RJ, Woods WG, Lange RB, Gerbing RB, Buxton AB, Neudorf S, Sanders J, Smith FO, Feig SA. Postremission therapy for children with acute myeloid leukemia: The children's cancer group experience in the transplant era Leukemia. 19: 965-970. PMID 15830007 DOI: 10.1038/Sj.Leu.2403763 |
0.375 |
|
| 2005 |
Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, Alonzo TA. Mortality in overweight and underweight children with acute myeloid leukemia Journal of the American Medical Association. 293: 203-211. PMID 15644547 DOI: 10.1001/Jama.293.2.203 |
0.426 |
|
| 2005 |
Alonzo TA. Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests Statistics in Medicine. 24: 403-417. PMID 15543634 DOI: 10.1002/Sim.1959 |
0.309 |
|
| 2005 |
Gregory J, Kim H, Alonzo T, Gerbing R, Ogden A, Woods W, Weinstein H, Shepherd L, Schiffer C, Appelbaum F, Willman C, Wiernik P, Rowe J, Tallman M, Feusner J. Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL). Blood. 106: 894-894. DOI: 10.1182/Blood.V106.11.894.894 |
0.374 |
|
| 2005 |
Aplenc R, Alonzo TA, Gerbing R, Smith FO, Eric S, Arceci RJ. Treatment of Children with Relapsed Acute Myeloid Leukemia with Gemtuzumab in Combination with Mitoxantrone and Cytarabine. Blood. 106: 4641-4641. DOI: 10.1182/Blood.V106.11.4641.4641 |
0.351 |
|
| 2005 |
Wright JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Radich JP, Bernstein ID, Meshinchi S. Clonal Involvement of the CD34+CD33− Progenitor Population by Leukemic Cells Harboring FLT3/ITD Correlates with High Risk of Relapse in Pediatric Acute Myeloid Leukemia. Blood. 106: 227-227. DOI: 10.1182/Blood.V106.11.227.227 |
0.394 |
|
| 2005 |
Lange BJ, Smith FO, Dinndorf PA, Arndt CA, Barnard DR, Dusenbery K, Feig SA, Feusner JH, Luna-Fineman S, Neglia J, Seibel NL, Sender L, Shannon KM, Weiman M, Gerbing RB, ... Alonzo TA, et al. Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML). Blood. 106: 169-169. DOI: 10.1182/Blood.V106.11.169.169 |
0.354 |
|
| 2005 |
Alonzo TA, Pepe MS. Assessing accuracy of a continuous screening test in the presence of verification bias Journal of the Royal Statistical Society. Series C: Applied Statistics. 54: 173-190. DOI: 10.1111/J.1467-9876.2005.00477.X |
0.539 |
|
| 2004 |
Loh ML, Reynolds MG, Vattikuti S, Gerbing RB, Alonzo TA, Carlson E, Cheng JW, Lee CM, Lange BJ, Meshinchi S. PTPN11 mutations in pediatric patients with acute myeloid leukemia: Results from the children's cancer group Leukemia. 18: 1831-1834. PMID 15385933 DOI: 10.1038/Sj.Leu.2403492 |
0.394 |
|
| 2004 |
Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood. 104: 3058-63. PMID 15217837 DOI: 10.1182/Blood-2003-12-4347 |
0.401 |
|
| 2004 |
Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition Blood. 104: 1841-1849. PMID 15166029 DOI: 10.1182/Blood-2004-03-1034 |
0.389 |
|
| 2004 |
Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, Barnard DR, Wallace JD, Kalousek D, Lange BJ, Woods WG. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 103: 3655-61. PMID 14751924 DOI: 10.1182/Blood-2003-08-2705 |
0.434 |
|
| 2004 |
Alonzo TA, Braun TM, Moskowitz CS. Small sample estimation of relative accuracy for binary screening tests. Statistics in Medicine. 23: 21-34. PMID 14695637 DOI: 10.1002/Sim.1598 |
0.517 |
|
| 2004 |
Slovak ML, Bloomfield CD, Gundacker H, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Willman C, Ravindranath Y, Alonzo TA, Carroll A, Hirsch B, Raimondi S, Heerema NA. Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. Blood. 104: 567-567. DOI: 10.1182/Blood.V104.11.567.567 |
0.421 |
|
| 2004 |
Loew TW, Gamis A, Smith FO, Massey GV, Woods WG, Hilden JM, Lange B, Alonzo TA, Chang M, Gerbing RB. Induction Therapy Failures in Down Syndrome Patients with Acute Myelogenous Leukemia. Blood. 104: 4527-4527. DOI: 10.1182/Blood.V104.11.4527.4527 |
0.408 |
|
| 2004 |
Loew TW, Gamis A, Smith FO, Massey GV, Woods WG, Hilden JM, Lange B, Alonzo TA, Chang M, Gerbing RB. Down Syndrome Patients with Relapsed Acute Myelogenous Leukemia. Blood. 104: 4526-4526. DOI: 10.1182/Blood.V104.11.4526.4526 |
0.428 |
|
| 2004 |
Hasle H, Alonzo T, Avrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Harbott J, Harrison CJ, van den Heuvel-Eibrink M, Kaspers G, Locatelli F, Nöllke P, et al. Monosomy 7 and Deletion 7q in Childhood AML. A Collaborative Study of 20 Study Groups. Blood. 104: 402-402. DOI: 10.1182/Blood.V104.11.402.402 |
0.356 |
|
| 2004 |
Mehta PA, Alonzo TA, Gerbing RB, Perentesis JP, Lange BJ, Davies SM. XPD Lys751Gln Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia. Blood. 104: 3016-3016. DOI: 10.1182/Blood.V104.11.3016.3016 |
0.37 |
|
| 2004 |
Mehta PA, Alonzo TA, Elliot JS, Gerbing RB, Wilke TA, Perentesis JP, Lange BJ, Davies SM. FAS Promoter Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia. Blood. 104: 3011-3011. DOI: 10.1182/Blood.V104.11.3011.3011 |
0.392 |
|
| 2003 |
Dusenbery KE, Howells WB, Arthur DC, Alonzo T, Lee JW, Kobrinsky N, Barnard DR, Wells RJ, Buckley JD, Lange BJ, Woods WG. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. Journal of Pediatric Hematology/Oncology. 25: 760-8. PMID 14528097 DOI: 10.1097/00043426-200310000-00004 |
0.387 |
|
| 2003 |
Alonzo TA, Pepe MS, Lumley T. Estimating disease prevalence in two-phase studies. Biostatistics (Oxford, England). 4: 313-26. PMID 12925524 DOI: 10.1093/Biostatistics/4.2.313 |
0.515 |
|
| 2003 |
Casillas JN, Woods WG, Hunger SP, McGavran L, Alonzo TA, Feig SA. Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. Journal of Pediatric Hematology/Oncology. 25: 594-600. PMID 12902910 DOI: 10.1097/00043426-200308000-00002 |
0.388 |
|
| 2003 |
Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951 Journal of Clinical Oncology. 21: 2940-2947. PMID 12885813 DOI: 10.1200/Jco.2003.06.128 |
0.438 |
|
| 2003 |
Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood. 102: 1474-9. PMID 12702504 DOI: 10.1182/Blood-2003-01-0137 |
0.393 |
|
| 2003 |
Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, Arceci RJ, Woods WG, Loken MR. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 101: 3398-406. PMID 12506020 DOI: 10.1182/Blood-2002-10-3064 |
0.437 |
|
| 2002 |
Alonzo TA, Pepe MS. Distribution-free ROC analysis using binary regression techniques. Biostatistics (Oxford, England). 3: 421-32. PMID 12933607 DOI: 10.1093/Biostatistics/3.3.421 |
0.538 |
|
| 2002 |
Alonzo TA, Kobrinsky NL, Aledo A, Lange BJ, Buxton AB, Woods WG. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group. Journal of Pediatric Hematology/Oncology. 24: 627-35. PMID 12439034 DOI: 10.1097/00043426-200211000-00006 |
0.388 |
|
| 2002 |
Chen AR, Alonzo TA, Woods WG, Arceci RJ. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American view. British Journal of Haematology. 118: 378-84. PMID 12139721 DOI: 10.1046/J.1365-2141.2002.03701.X |
0.302 |
|
| 2002 |
Barnard DR, Lange B, Alonzo TA, Buckley J, Kobrinsky JN, Gold S, Neudorf S, Sanders J, Burden L, Woods WG. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 100: 427-34. PMID 12091332 DOI: 10.1182/Blood.V100.2.427 |
0.426 |
|
| 2002 |
Wells RJ, Arthur DC, Srivastava A, Heerema NA, Le Beau M, Alonzo TA, Buxton AB, Woods WG, Howells WB, Benjamin DR, Betcher DL, Buckley JD, Feig SA, Kim T, Odom LF, et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia. 16: 601-7. PMID 11960339 DOI: 10.1038/Sj.Leu.2402390 |
0.434 |
|
| 2002 |
Alonzo TA, Pepe MS, Moskowitz CS. Sample size calculations for comparative studies of medical tests for detecting presence of disease. Statistics in Medicine. 21: 835-52. PMID 11870820 DOI: 10.1002/Sim.1058 |
0.656 |
|
| 2001 |
Pepe MS, Alonzo TA. Comparing disease screening tests when true disease status is ascertained only for screen positives. Biostatistics (Oxford, England). 2: 249-60. PMID 12933537 DOI: 10.1093/Biostatistics/2.3.249 |
0.54 |
|
| 2001 |
Hadgu A, Miller W, Pepe MS, Alonzo TA. Using a combination of reference tests to assess the accuracy of a diagnostic test (multiple letters) Statistics in Medicine. 20: 656-660. PMID 11223907 DOI: 10.1002/Sim.762 |
0.468 |
|
| 2000 |
Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs Biometrics. 56: 345-351. PMID 10877288 DOI: 10.1111/J.0006-341X.2000.00345.X |
0.493 |
|
| 1999 |
Alonzo TA, Pepe MS. Using a combination of reference tests to assess the accuracy of a new diagnostic test. Statistics in Medicine. 18: 2987-3003. PMID 10544302 DOI: 10.1002/(Sici)1097-0258(19991130)18:22<2987::Aid-Sim205>3.0.Co;2-B |
0.548 |
|
| 1999 |
Lee RY, Artun J, Alonzo TA. Are dental anomalies risk factors for apical root resorption in orthodontic patients? American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics. 116: 187-195. PMID 10434093 DOI: 10.1016/S0889-5406(99)70217-9 |
0.344 |
|
| Show low-probability matches. |